63.4% (± 6.4%) of all CD8+ T cells were LSD1+EOMES+PD-1+ in resistant melanoma patients, compared to only 30% (± 5.4%) in responder patients and 5.5% (± 0.62%) in healthy donors (Figure 6B). This evidence concerns the gene CD8A and melanoma.